{"entity":{"id":"paper-saidu-cancer-medicines-barriers-cameroon-pgph-2026","kind":"paper","name":"Barriers to good-quality cancer medicines in Cameroon, as regulators and frontline staff see them","aka":[],"tldr":"Interviews with 57 people across Cameroon's chemotherapy supply chain found weak regulation, underfunded regulatory work and high prices encouraging substandard cancer medicines and treatment.","summary":"Published as \"Barriers to accessing high-quality cancer medicines in Cameroon. A qualitative study of the views and practices of regulators and frontline healthcare providers\". A cross-sectional qualitative study combining a document review with interviews of 57 stakeholders working in regulation, procurement, quality control and use of chemotherapy: 25 pharmacists, 14 medical oncologists, 12 oncology nurses, five drug distributors and one regulator, interviewed in Yaoundé and Douala in October 2023.","asOf":"2026-11-11","links":[{"label":"PLOS Glob Public Health 2026","url":"https://doi.org/10.1371/journal.pgph.0005370"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/41576006/"}],"tags":[],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["dpml-cameroon","cameroon-ministry-of-public-health"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"journal":"PLOS Global Public Health","year":2026,"doi":"10.1371/journal.pgph.0005370","pmid":"41576006","authors":"Saidu Y, Makia MC, Frambo A, et al.","paperType":"observational","findings":["Weak regulatory systems, inadequate funding for regulatory activities and a lack of core competencies among regulatory staff affected the quality of chemotherapy medicines.","The high cost of cancer medicines affected access to quality products and the care given to patients who could not afford high-priced products.","With no point-of-care testing tools, these weaknesses appeared to encourage substandard medicines and the use of substandard therapies or protocols."],"whatItMeans":"Cancer medicines in Cameroon are often paid for by families, and the people who regulate and use them describe a market where cheaper products of uncertain quality fill the gap.","caveats":["Qualitative; it does not measure how many products are substandard."],"participants":57},"route":"/key-papers/paper-saidu-cancer-medicines-barriers-cameroon-pgph-2026/","neighbours":{"institution":[{"id":"dpml-cameroon","kind":"institution","name":"Department of Pharmacy, Medicines and Laboratories, Cameroon (DPML)","route":"/institutions/dpml-cameroon/"},{"id":"cameroon-ministry-of-public-health","kind":"institution","name":"Ministry of Public Health, Cameroon (MINSANTE)","route":"/institutions/cameroon-ministry-of-public-health/"}]}}